Alzheimer's Disease
Conditions
Keywords
Alzheimer's disease, retrospective, Axona
Brief summary
This evaluation of the efficacy and safety of AXONA will be a chart review carried out at 16 practices in which AXONA has been prescribed for the treatment of patients with mild-to-moderate AD. Efficacy of AXONA will be assessed by comparison of patient status before and after initiation of treatment.
Detailed description
The primary objective is to assess the efficacy of AXONA (medium chain triglycerides \[MCTs\]) when used alone or in combination with other agents in patients with mild-to-moderate Alzheimer's disease (AD) in routine clinical practice.
Interventions
None listed
Sponsors
Cerecin
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patient Inclusion Criteria: * Male or female outpatients aged ≥ 50 years with a diagnosis of probable AD of mild-to-moderate severity * MMSE score between 14 and 24 inclusive at the initiation of AXONA treatment (if available) * Has received Axona for a duration of ≥ 6 months Caregiver Inclusion Criteria (if applicable): * Must be at least 21 years of age, has been the primary caregiver since prior to the initiation of Axona, provides at least 4 hours of supervision or direct assistance per day for the patient and is able to perform assessments. Patient
Exclusion criteria
* MMSE score \< 14 at the time when AXONA treatment was initiated * Presence of co-morbid disease known to adversely impact cognitive function (e.g., Parkinson's disease, history of cerebral infarcts, dementia with Lewy bodies) * Vascular dementia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physician's Overall Assessment of Patient Status at the beginning of Axona treatment and the most recent assessment | 6 months post the start date of Axona |
Secondary
| Measure | Time frame |
|---|---|
| Changes from baseline in patient's living situation | 6 months post the start date of Axona |
| Changes from baseline in patient's medications for the treatment of AD | 6 months post the start date of Axona |
| Changes from baseline in patient's medications for psychiatric conditions related to AD | 6 months post the start date of Axona |
| Changes from baseline in patient's memory and ability to carry out instrumental activities of daily living as assessed by caregivers | 6 months post the start date of Axona |
| Adverse events assessed by physician's as being possibly associated with the use of Axona | 6 months post the start date of Axona |
Outcome results
None listed